Chimeric antigen receptor (CAR) T cell therapy has recently emerged as an innovative treatment option for cancer patients. Although it has been successful, this new method faces acknowledged limitations and potential toxicities, including antigen escape, on-target off-tumor effects, and an immunosuppressive microenvironment.
To overcome the shortcomings linked to traditional CAR-T therapy, scientists are investigating novel CAR strategies, such as dual or tandem CAR expression, CAR structure remodulation, and combination immunotherapies with checkpoint blockade.
An alternative technique utilizes immune cell types such as natural killer (NK) cells in CAR-based therapies. CAR-NK cell therapies, developed using the same receptor-antigen hybrid technology as CAR-T, express the CAR in NK cells.
In comparison to CAR-T therapy, CAR-NK cell therapy is deemed safer and is associated with a reduced risk of adverse immune side effects. Clinical trials have shown promising results for CAR-NK cell therapies in solid tumors and hematological malignancies.
Within this framework, this session will focus on how Sino Biological is leading the way in supporting the development of CAR-T and CAR-NK cell therapies with comprehensive solutions. These solutions cover every stage, including CAR development, CAR-T and CAR-NK cell preparation, and quality control for CAR-T/ CAR-NK cells.
Learning objectives
- Summarize the various CAR-associated cellular immunotherapies in clinical use.
- Examine existing challenges and explore possible approaches in CAR-associated cellular immunotherapy.
- Discuss Sino Biological solutions in supporting CAR-T therapy and CAR-NK cell therapy development.
Keynote speaker
Qiongsi (Alston) Zhang, Ph.D., Senior Product Scientist
Dr. Qiongsi Zhang is a Senior Product Scientist at Sino Biological, specializing in the development and optimization of products. He earned his Ph.D. in Toxicology and Cancer Biology from the Markey Cancer Center at the University of Kentucky. His research centered on the carcinogenic effects of heavy metals and employing multi-omics approaches to address drug resistance in advanced prostate cancer.
Dr. Zhang has extensive expertise in areas such as cell signaling, cancer research using in vitro and in vivo models, multi-omics data analysis, and cancer immunology.